Publications by authors named "J L Addison"
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on SB5, an adalimumab biosimilar approved in Europe in 2017, and aims to gather real-world data on its usage and effectiveness in patients with various immune-mediated inflammatory diseases (IMIDs).
- Researchers analyzed clinical and healthcare claims data from the French national healthcare database to assess patient persistence on SB5 after 12 months.
- Among 911 patients treated with SB5, notable remission rates were observed at the 12-month mark, particularly in naïve patients, across various conditions such as rheumatoid arthritis and Crohn's disease, with all showing significant improvement from baseline.
Article Synopsis
- The study investigated the efficacy and safety of the biosimilar BAT1806/BIIB800 compared to the reference drug tocilizumab (TCZ) in patients with moderate-to-severe rheumatoid arthritis over a treatment period of 24-48 weeks.
- Results showed that the effectiveness of both treatments was similar, with high response rates (ACR20), along with comparable safety and immunogenicity profiles across treatment groups.
- Overall, the study concluded that BAT1806/BIIB800 has similar therapeutic outcomes to TCZ, supporting its use as a treatment option for rheumatoid arthritis patients.